Glenmark focuses on respiratory and dermatology pipeline, shares watched amid sector moves

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 18:11.

Glenmark Pharmaceuticals (INE935A01035) sits in the Indian mid-cap pharma segment and trades on the NSE and BSE in Mumbai. The company continues to build out its respiratory and dermatology franchise, a focus that positions Glenmark alongside peers such as Sun Pharma and Dr Reddys Laboratories in the global generics and specialty medicines market.

Pipeline and portfolio focus in India

Glenmark Pharmaceuticals Ltd. highlights three core areas in its business model: respiratory, dermatology and oncology, supported by a portfolio of branded generics and specialty products targeted mainly at emerging markets. The company stresses its research capabilities through dedicated R&D centers in India and abroad, with efforts directed at both small molecules and complex generics according to its latest corporate profile on the investor relations site. Glenmark investor relations overview

In respiratory, Glenmark has developed a range of inhaled therapies, including fixed-dose combinations and devices designed for asthma and chronic obstructive pulmonary disease patients, reflecting a long-standing focus on airway diseases. In dermatology, formulations for psoriasis, eczema and other inflammatory skin disorders form a key part of its prescription offering, while oncology efforts include targeted therapies and support medications aimed at cancer care settings, often marketed in India and selected international territories.

Friday focus on sector and peers

On Fridays, many investors look across the broader Indian pharmaceutical sector to compare companies such as Glenmark with larger listed peers on the NSE and BSE. Sector reports regularly benchmark Glenmark against Sun Pharmaceutical Industries, Cipla, Lupin and Dr Reddys Laboratories on metrics such as revenue mix, export exposure and research intensity, giving retail investors a clearer picture of where Glenmark stands in the competitive landscape. Reuters overview of Indian pharma sector trends

Analyst commentary from local brokerage and global houses typically emphasizes regulatory compliance, U.S. Food and Drug Administration plant observations and pricing pressure risks in the U.S. generics market for Indian manufacturers, factors that also apply to Glenmark. Consensus data from market services show that Glenmark is generally viewed as a mid-tier Indian pharma name with exposure to regulated markets and a meaningful share of revenue from domestic formulations, a profile that can lead to earnings volatility when currency movements or regulatory events affect export-focused units. MarketScreener analyst and consensus snapshot on Glenmark

How Glenmark makes its money

Glenmark Pharmaceuticals generates most of its revenue from manufacturing and marketing branded generics and specialty medicines across India, Latin America, Russia and other emerging markets. Respiratory and dermatology products form two key pillars, while U.S. and European generics add exposure to regulated markets and require ongoing compliance investments in manufacturing quality and documentation.

Where the stock trades today

Glenmark Pharmaceuticals shares trade on the NSE and BSE in Mumbai, with prices quoted in Indian rupees; recent data from Indian exchanges show the stock changing hands in the mid-cap range, though the latest exact price should be checked on the official NSE or BSE quote pages for the most current figure.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.